BRD9 determines the cell fate of hematopoietic stem cells by regulating chromatin state
Muran Xiao,Shinji Kondo,Masaki Nomura,Shinichiro Kato,Koutarou Nishimura,Weijia Zang,Yifan Zhang,Tomohiro Akashi,Aaron Viny,Tsukasa Shigehiro,Tomokatsu Ikawa,Hiromi Yamazaki,Miki Fukumoto,Atsushi Tanaka,Yasutaka Hayashi,Yui Koike,Yumi Aoyama,Hiromi Ito,Hiroyoshi Nishikawa,Toshio Kitamura,Akinori Kanai,Akihiko Yokoyama,Tohru Fujiwara,Susumu Goyama,Hideki Noguchi,Stanley C. Lee,Atsushi Toyoda,Kunihiko Hinohara,Omar Abdel-Wahab,Daichi Inoue
DOI: https://doi.org/10.1038/s41467-023-44081-6
IF: 16.6
2023-12-15
Nature Communications
Abstract:Abstract ATP-dependent chromatin remodeling SWI/SNF complexes exist in three subcomplexes: canonical BAF (cBAF), polybromo BAF (PBAF), and a newly described non-canonical BAF (ncBAF). While cBAF and PBAF regulate fates of multiple cell types, roles for ncBAF in hematopoietic stem cells (HSCs) have not been investigated. Motivated by recent discovery of disrupted expression of BRD9, an essential component of ncBAF, in multiple cancers, including clonal hematopoietic disorders, we evaluate here the role of BRD9 in normal and malignant HSCs. BRD9 loss enhances chromatin accessibility, promoting myeloid lineage skewing while impairing B cell development. BRD9 significantly colocalizes with CTCF, whose chromatin recruitment is augmented by BRD9 loss, leading to altered chromatin state and expression of myeloid-related genes within intact topologically associating domains. These data uncover ncBAF as critical for cell fate specification in HSCs via three-dimensional regulation of gene expression and illuminate roles for ncBAF in normal and malignant hematopoiesis.
multidisciplinary sciences